Acumen Pharmaceuticals Inc ABOS
$2.15
▼ -0.92%
($-0.02)
⬆️ Above Yest. High
🗓️ Earnings Next Week
Open
$2.21
Prev Close
$2.17
Day Range
$2.12 – $2.35
52W Range
$1.19 – $3.60
Market Cap
$155.29M
Beta
0.33
EPS (TTM)
$-1.86
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2021-07-01 |
| Shares Out. | 72,230,000 |
| Website | acumenpharm.com/ ↗ |
| Phone | 16173444190 |
| Employees | 61 |
| Net Income | -$20.7M |
| Free Cash Flow | -$105.6M |
| Total Assets | $133.6M |
| Total Liabilities | $46.2M |
| Equity | $87.5M |
About Acumen Pharmaceuticals Inc
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.
Acumen Pharmaceuticals Inc is a publicly traded company under the ticker symbol ABOS on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
12 analysts (2026-07-01)